10 percent
How much of 2022’s revenue in major pharma was from new drugs…?
This most recent snapshot from the 2023 Innovation Index - the ‘Freshness Index’ - remains fascinating - if you take the bottom 20, just ten percent of 2022’s revenue was from drugs launched in the past 5 years. And that includes major players - 12 approvals contributed to just 8% of Novartis’ 2022, 10 drugs to 2% of Sanofi’s.
If you think all launches are equal, clearly the figures show a different story.
I’ll reveal more in the next article or two…